Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Replay

Request full access

Reprogramming biology by writing and delivering big DNA

San Diego, United StatesFounded 2020Biotech & Life Sciences

About Replay

Replay.bio is a cutting-edge biotechnology startup focused on developing advanced genomic products. The company specializes in creating synthetic gene libraries, which are collections of artificially synthesized genes. These libraries are used to design, write, and deliver large-scale DNA sequences. Replay.bio's technology allows for the rapid and cost-effective synthesis of genes, optimizing and rewriting gene sequences to improve their functionality.

Replay.bio operates in the genomic and biotechnology market, serving clients such as research institutions, pharmaceutical companies, and healthcare providers. The company’s products have a wide range of applications, including writing simple genomes (like viral and bacterial genomes), complex genomes (such as synthetic human chromosomes), and even entire synthetic genomes for plants, fungi, and mammals.

The business model of Replay.bio revolves around providing specialized genomic products and services. They generate revenue by selling their synthetic gene libraries and offering custom gene synthesis services. Additionally, they collaborate with other companies and research institutions to develop new genomic therapies. For instance, Replay.bio has partnered with Syena, an oncology-focused product company, and the University of Texas MD Anderson Cancer Center to create advanced cell therapies for cancer treatment. These therapies combine the safety and efficacy of Natural Killer (NK) cells with the targeting ability of T Cell Receptors (TCRs) to fight tumors.

Replay.bio makes money through direct sales of their genomic products, licensing their technologies, and forming strategic partnerships for co-development of new therapies. Their innovative approach and advanced technologies position them as a key player in the rapidly growing field of genomics and synthetic biology.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
31
Open positions
None listed
Dealroom signal
69.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Sustainable Development Goals, Biotech and Pharma, Climate Tech, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Apr 2026 $0 — LEO pharma ↗
GRANTOther financing Nov 2022 $1.6M — Bill & Melinda Gates Foundation ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Replay website traffic

Latest recorded traffic for Replay is 2.1K monthly website visits, down 38.2% over the last three months. Replay's team declined 13.9% over the past year.

Latest monthly visits2.1K 3-month web change-38.2% 1-year team growth-13.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Replay in the San Diego ecosystem

Live from Dealroom

The Replay office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed8 investors entered at this stage

  • KKR
  • OMX Ventures
  • Axial
  • Lansdowne Partners
  • Artis Ventures
  • Salt
  • DeciBio
  • Bill & Melinda Gates Foundation

Other known investors2 additional known investors

  • LEO pharma
  • University of Pittsburgh
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States93.3%
🇬🇧 United Kingdom6.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Replay on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Replay’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.